STOCK TITAN

Merus to Participate in a Fireside Chat at the 33rd Annual Roth Conference

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Rhea-AI Summary

Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that CEO Bill Lundberg, M.D., will participate in a fireside chat at the 33rd Annual Roth Conference on March 15, 2021, at 2:00 p.m. ET. The event will be accessible via a live webcast on the Company’s Investors page, with an archived version available for a limited time afterward.

Merus is known for developing innovative, full-length multispecific antibodies, branded as Biclonics® and Triclonics®, which have shown promising features in clinical studies.

Loading...
Loading translation...
Argus Session date unavailable
-0.35% session move Open Argus
Details

News Market Reaction – MRUS

The recorded move for MRUS in the trading session of this news was -0.35%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 08, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., Chief Executive Officer, will participate in a fireside chat at the 33rd Annual Roth Conference on Monday, March 15 at 2:00 p.m. ET.

The live webcast of the presentation will be available on the Investors page of the Company's website, https://ir.merus.nl. An archived presentation will be available on the Merus website for a limited time.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, http://www.merus.nl and https://twitter.com/MerusNV.


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Merus participate in the Roth Conference?

Merus will participate in the 33rd Annual Roth Conference on March 15, 2021, at 2:00 p.m. ET.

Who is the CEO of Merus?

The CEO of Merus is Bill Lundberg, M.D.

Where can I watch the live webcast of Merus at the Roth Conference?

The live webcast can be viewed on Merus' Investors page at their website.

What type of products does Merus develop?

Merus develops innovative full-length multispecific antibodies, known as Biclonics® and Triclonics®.

What stock symbol is associated with Merus?

The stock symbol for Merus is MRUS.

Keep reading